These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 15188371

  • 21. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
    Kalden JR, Schattenkirchner M, Sörensen H, Emery P, Deighton C, Rozman B, Breedveld F.
    Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH, M02-570 Study Group.
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [Abstract] [Full Text] [Related]

  • 23. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
    Goldenberg MM.
    Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
    [Abstract] [Full Text] [Related]

  • 24. Leflunomide: new indication. In psoriatic rheumatism: too many risks, too little efficacy.
    Prescrire Int; 2005 Aug; 14(78):123-6. PubMed ID: 16106593
    [Abstract] [Full Text] [Related]

  • 25. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.
    Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, McCune WJ.
    J Rheumatol; 1995 May; 22(5):894-8. PubMed ID: 8587078
    [Abstract] [Full Text] [Related]

  • 26. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
    Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C.
    Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
    [Abstract] [Full Text] [Related]

  • 27. Leflunomide in psoriatic arthritis: results from a large European prospective observational study.
    Behrens F, Finkenwirth C, Pavelka K, Štolfa J, Šipek-Dolnicar A, Thaçi D, Burkhardt H.
    Arthritis Care Res (Hoboken); 2013 Mar; 65(3):464-70. PubMed ID: 23042698
    [Abstract] [Full Text] [Related]

  • 28. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
    Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C, IMPACT 2 Study Group.
    Ann Rheum Dis; 2007 Apr; 66(4):498-505. PubMed ID: 17114188
    [Abstract] [Full Text] [Related]

  • 29. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis.
    van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE.
    Ann Rheum Dis; 2005 Dec; 64(12):1761-4. PubMed ID: 15901634
    [Abstract] [Full Text] [Related]

  • 30. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial.
    Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M, Fletcher MJ, Chasan-Taber S, Finger E, Morales A, Le CH, Trentham DE.
    Arthritis Rheum; 1998 Feb; 41(2):290-7. PubMed ID: 9485087
    [Abstract] [Full Text] [Related]

  • 31. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
    Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A.
    Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
    [Abstract] [Full Text] [Related]

  • 32. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
    Mulder MLM, Vriezekolk JE, den Broeder N, Mahler EAM, Helliwell PS, van den Hoogen FHJ, den Broeder AA, Wenink MH.
    Trials; 2020 Feb 10; 21(1):155. PubMed ID: 32041657
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.
    Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, Sugawara S.
    J Rheumatol; 2004 Feb 10; 31(2):243-51. PubMed ID: 14760792
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
    Gibofsky A, Rodrigues J, Fiechtner J, Berger M, Pan S.
    Clin Ther; 2007 Jun 10; 29(6):1071-85. PubMed ID: 17692722
    [Abstract] [Full Text] [Related]

  • 35. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL.
    Arthritis Rheum; 2012 Oct 10; 64(10):3156-67. PubMed ID: 22806399
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M.
    Clin Ther; 2009 Aug 10; 31(8):1754-64. PubMed ID: 19808134
    [Abstract] [Full Text] [Related]

  • 37. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
    Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P.
    Ann Rheum Dis; 2005 Jan 10; 64(1):44-51. PubMed ID: 15271770
    [Abstract] [Full Text] [Related]

  • 38. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms.
    Williams GW, Kivitz AJ, Brown MT, Verburg KM.
    Clin Ther; 2006 Feb 10; 28(2):204-21. PubMed ID: 16678642
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 10; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial.
    Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA, Tcrolimus Rheumatoid Arthritis Study Group.
    Arthritis Rheum; 2003 Dec 10; 48(12):3328-37. PubMed ID: 14673984
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.